AIM ImmunoTech Inc. AIM
0.16 USD 0.00 (-2.55%)
Nov 5, 2026, 1:09 PM EST
0.153 Day range 0.1725
0.15 52-week range 1.82
- YTD
- -85.74%
- 1 year
- -90.98%
News
globenewswire.com AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer New investor presentation outlines scientific rationale for combining Ampligen's immune-stimulating activity with daraxonrasib's targeted RAS inhibition to potentially prolong clinical benefit
globenewswire.com AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays CEO interview explores Ampligen's potential to extend survival and improve quality of life as AIM advances toward pivotal development
globenewswire.com AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense Potential OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage of the antiviral potential of Ampligen®…
globenewswire.com AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data Recent biotech media features focus on Ampligen's potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program Recent biotech media…
proactiveinvestors.com Ionic Rare Earths targets AIM listing as Belfast magnet recycling strategy gathers pace Ionic Rare Earths Ltd (ASX:IXR, OTC:IXRRF) is advancing plans to list its shares on London's AIM market in the fourth quarter of 2026 as it builds its UK presence and progresses commercialisation of…
globenewswire.com AIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones
proactiveinvestors.com Ondine Biomedical pauses trading to raise fresh investment after positive phase III result Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the developer of light-activated nasal disinfection for hospital patients, has suspended trading in its shares while it raises new investment to capitalise…
proactiveinvestors.com 1947 Oil & Gas starts AIM trading after £50m fundraising and Gulf acquisition 1947 Oil & Gas, a newly listed oil and gas producer focused on US assets, began trading on London's AIM market on Monday with an initial valuation of about £65 million. The company issued 500 million…
proactiveinvestors.com 1947 Oil & Gas makes AIM debut with ambitions to grow production sharply in coming years 1947 Oil & Gas PLC (AIM:1947) begins trading on AIM today, with shares marked at a premium price and ambitions to lift production from its newly acquired US Gulf of America assets by around 50% over…
proactiveinvestors.com Digitalbox eyes creator-led growth as it rides out Meta disruption Digitalbox PLC (AIM:DBOX, FRA:RLXB), the mobile-first digital media group behind The Daily Mash and The Tab, believes the upheaval sweeping digital media presents significant opportunities for nimble…
globenewswire.com AIM ImmunoTech Highlights Ampligen's Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines' Daraxonrasib Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer Survival data highlighted in accompanying chart show Ampligen-associated median overall…
proactiveinvestors.com Shore Capital cheers Coiled Therapeutics dosing progress Shore Capital has welcomed the latest step forward in Coiled Therapeutics' (AIM:COIL, OTCQB:COTXF) cancer drug trial, reiterating its support for the AIM-listed group. The broker was responding to…
proactiveinvestors.com Coiled Therapeutics fills two cohorts as reworked cancer drug advances Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) has enrolled the first patients into two dose groups testing a reformulated version of its experimental cancer drug. The AIM-listed oncology group said it…
proactiveinvestors.co.uk Kefi confirms staff safe after fatal Tulu Kapi attack as local investors step up KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF, FRA:KMSA), the AIM-listed explorer developing the Tulu Kapi gold project in Ethiopia, said all employees affected by last week's security incident have…
proactiveinvestors.co.uk Sintana Energy advances deal to acquire KON-16 in Angola Sintana Energy Inc (TSX-V:SEI, OTCQB:SEUSF, FRA:3ZX1, AIM:SEI) has signed definitive agreements for its proposed entry into Angola's Block KON-16, securing an indirect 5% participating interest as…
globenewswire.com AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video Company continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen's potential to reshape the tumor microenvironment and enhance checkpoint inhibition
proactiveinvestors.co.uk Ondine Biomedical strikes deal with Mexico's largest private hospital network Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the AIM-listed company behind light-activated antimicrobial therapies, has agreed a partnership with Hospital Ángeles, Mexico's largest private healthcare…
globenewswire.com AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Redhill Biopharma (NASDAQ:RDHL) stock increased by 69.4% to $1.12 during Monday's regular session. The company's market cap stands at $4.0 million. CollPlant Biotechnologies (NASDAQ:CLGN)…
globenewswire.com AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 OCALA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office has granted a…
proactiveinvestors.co.uk Metals One partner rejects claim that Barbrook mine deal has failed Lions Bay Resources has rejected a claim by Vantage Goldfields that its proposed acquisition of the Barbrook gold mine in South Africa has failed, describing the statement as false and misleading.…
globenewswire.com AIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand Conference Video webcast now available here
benzinga.com Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $7 Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $9 to $7.- benzinga.com AIM ImmunoTech Q2 EPS $(0.43) Misses $(0.18) Estimate, Sales $26.000K Up From $25.000K YoY AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.18) by 138.89 percent. This is a 88.32 percent increase over losses of…
benzinga.com AIM ImmunoTech Announces Final Subjects Receives Last Dose Of Ampligen Under Study Protocol In Phase 2 DURIPANC Clinical Study AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the final subject has received their last dose of Ampligen® (rintatolimod) under the study protocol, reaching this…
benzinga.com AIM ImmunoTech Outlines Upcoming Milestones, Including DURIPANC Primary Endpoint Analysis Expected In December 2026 At the center of AIM's strategy is Ampligen® (rintatolimod), the Company's proprietary TLR3 agonist immunotherapy, which is being evaluated in the ongoing Phase 2 DURIPANC study in combination with- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com AIM ImmunoTech Commences ~$2.65M Registered Direct Offering Of 2.554M Common Shares At $0.5189/Share AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), today announced that it has entered into definitive agreements for a registered direct offering and concurrent private placement priced…
- benzinga.com AIM ImmunoTech Files Prospectus For Resale Of Up To 31,287,933 Shares This prospectus relates to the offering and resale by the Selling Stockholders listed herein of up to an aggregate of 31,287,933 shares of our common stock, par value $0.001 per share (the "Common…
benzinga.com AIM ImmunoTech Reports Positive Phase 2 DURIPANC Update As Final Patient Enrolled In Pancreatic Cancer Trial AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive progress in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen® (rintatolimod)…- benzinga.com U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com AIM ImmunoTech Enrolls Final Participant In Its Phase 2 Clinical Study Of Ampligen Combined With AstraZeneca's Anti-PD-L1 Immune Checkpoint Inhibitor Imfinzi To Treat Metastatic Pancreatic Cancer AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced a significant milestone in its pancreatic cancer development program, with enrollment of the final subject, barring…
benzinga.com Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price targets raised/cut, ratings maintained/changed.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $9 Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $10 to $9.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com AIM ImmunoTech To Present Pre-Clinical Data On Potential Role Of Its Lead Drug Ampligen For Ebola Virus Treatment AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases,…
benzinga.com AIM ImmunoTech Announcing $2.4M Registered Direct Offering Of 7.5M Shares At $0.325 Each. AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company", today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Why Agilysys Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket Agilysys Inc (AGYS) shares rose in pre-market trading after reporting better-than-expected financial results and issuing positive sales guidance. Other notable gainers and losers in pre-market…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com AIM ImmunoTech Q1 EPS $(0.69) Down From $(0.05) YoY, Sales $22.000K Miss $100.000K Estimate AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.69) per share. This is a 1280 percent decrease over losses of $(0.05) per share from the same period last year. The company reported…